Affiliations: Department of Urology, College of Medicine, Chungbuk
National University, Cheongju, Chungbuk, South Korea | BK21 Chungbuk Biomedical Science Center, School of
Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea | Department of Food and Biotechnology, Chungju National
University, Chungju, South Korea | Department of Biochemistry, Dongeui University College
of Oriental Medicine and Department of Biomaterial Control (BK21 Program),
Dongeui University Graduate School, Busan, South Korea
Note: [] Corresponding author: WUN-JAE KIM M.D., Ph.D., Department of
Urology, College of medicine, Chungbuk National University 62, Kaeshin-dong,
Heungduk-ku, Cheongju, Chungbuk 361-711, Korea. Tel.: +82 43 269 6371; Fax: +82
43 269 6129; E-mail: wjkim@chungbuk.ac.kr
Abstract: Although polymorphisms in glutathione S-transferase (GST) have been
associated with the risk of bladder cancer (BC), few reports provide
information about the development of BC. The aim of the present study was to
investigate the effect of homozygous glutathione S-transferase-μ (GSTM1) and
glutathione S-transferase-� (GSTT1) deletions as prognostic markers in
non-muscle-invasive bladder cancer (NMIBC). A total of 241 patients with
primary NMIBC were enrolled in this study. GSTM1 and GSTT1 polymorphisms were
analyzed by multiplex polymerase chain reaction (PCR) using blood genomic DNA.
The results were compared with clinicopathological parameters. The prognostic
significance of the GSTs was evaluated by Kaplan-Meier and multivariate Cox
regression model. A statistically significant association between genotype and
histopathological parameter was not observed. The patients with the
GSTT1-positive genotype had significantly reduced recurrence- and
progression-free survival than those with the GSTT1-null genotype (log-rank
test, p< 0.05, respectively). Recurrence- and progression-free survival were
not related to the GSTM1 genotypes. In multivariate regression analysis, the
GSTT1-positive genotype was the independent predictor for recurrence [hazard
ratio (HR), 1.631; p=0.043] and progression (HR, 3.418; p=0.006). These results
suggested that the GSTT1 genotype could be a useful prognostic marker for
recurrence and progression in NMIBC.
